Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alcoholism
ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
July 10th, 2009
ALP Life Sciences, LLC (Company) announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM) whitepaper is available at www.ALPLifeSciences.com/wp. After completing initial research, the Company is pursuing clinical trials and FDA regulatory approval of Nanoveson(TM) as a prescription drug treatment for non-alcoholic fatty liver disease (NAFLD). Over 60 million adult Americans suffer from NAFLD and these numbers are rising rapidly. There is no FDA approved NAFLD treatment. NAFLD is a global health crisis. NAFLD is also associated with the metabolic syndrome and other life threatening diseases. NAFLD is known to progress to more advanced liver diseases such...
Source: Health Business Week (2009-07-10)
|
